Key points
- Genomics studies the entire genome at once, rather than one gene at a time.
- The human genome contains about 3 billion DNA base pairs and about 19,900 genes that provide instructions for making proteins.
- The Human Genome Project produced the first human genome sequence in 2003. A complete, gap-free sequence of 3.055 billion base pairs was published in 2022.
- In drug discovery, genomics helps identify which genes and proteins cause disease, so researchers can choose better drug targets.
- Drug programs whose targets have human genetic support have been about 2.6 times more likely to succeed than those without it.
Genomics is the study of an organism's entire genome: all of its DNA, including every gene and the stretches of DNA between them. The National Human Genome Research Institute describes it as the study of all of a person's genes, including how those genes interact with each other and with the person's environment.
Genomics matters for medicine because nearly every disease has some genetic component, and because the genome is now one of the most reliable guides to which experimental drugs are likely to work.
The genome in numbers
| Feature | Human genome |
|---|---|
| DNA base pairs | About 3 billion (3.055 billion in the first complete sequence) |
| Genes that provide instructions for making proteins | About 19,900 |
| Chromosomes | 23 pairs |
Sources: NHGRI; MedlinePlus Genetics; Nurk et al., Science (2022).
Only a small fraction of the genome codes directly for proteins. Much of the rest helps control when and where genes are switched on, and the function of large parts of it is still being studied.
Genetics versus genomics
Genetics traditionally studies individual genes and how particular traits or diseases are inherited, for example how a single faulty gene causes cystic fibrosis. Genomics looks at all the genes together. That makes it possible to study complex diseases, such as heart disease, diabetes, and most cancers, which involve many genes acting together and with the environment.
A short history
- 1990–2003: the Human Genome Project. An international effort launched in October 1990 produced the first sequence of the human genome, completed in April 2003.
- 2003 onward: cheaper, faster sequencing. New sequencing technologies cut the cost and time of reading a genome by several orders of magnitude, making it practical to sequence thousands, and then hundreds of thousands, of people.
- 2022: the complete sequence. The original reference genome left about 8% of the genome unfinished, mostly in highly repetitive regions. In 2022 the Telomere-to-Telomere Consortium published the first complete, gap-free sequence of a human genome, at 3.055 billion base pairs.
Major branches of genomics
| Field | What it studies |
|---|---|
| Structural genomics | The physical structure and sequence of the genome |
| Functional genomics | What genes and other DNA sequences actually do |
| Population genomics | How genetic variation differs across people and populations, and how it relates to disease |
| Cancer genomics | The DNA changes that arise in tumors |
| Pharmacogenomics | How genetic differences affect people's responses to drugs |
Related "omics" fields study the molecules the genome produces, such as RNA (transcriptomics) and proteins (proteomics).
How genomics changes drug discovery
Most drugs work by acting on a protein, and every protein is encoded by a gene. Genomics helps drug developers in three main ways.
1. Choosing better targets
The most expensive mistake in drug development is picking a target that turns out not to matter for the disease. Human genetics offers a natural experiment: if people who carry a variant that disables a gene are protected from a disease, a drug that blocks the same gene's protein may protect too.
Large analyses support this. A 2015 study in Nature Genetics found that genetic support roughly doubled the chance that a drug mechanism reached approval. A 2024 follow-up in Nature estimated that drug mechanisms with human genetic support were about 2.6 times more likely to succeed in clinical development than those without it.
2. A case study: PCSK9
In 2006, researchers reported in the New England Journal of Medicine that people carrying certain variants that disable the PCSK9 gene had lifelong lower LDL cholesterol. Among Black participants in the study, those with these variants had 28% lower LDL cholesterol and an 88% lower risk of coronary heart disease.
That finding pointed directly at a drug target. Drugs that block the PCSK9 protein were later developed and approved to lower LDL cholesterol. It is one of the clearest examples of a target discovered through human genetics.
3. Matching drugs to patients
Genomic testing can identify which patients are most likely to benefit from a drug, or most likely to be harmed by it. This is the basis of precision medicine. In industry data, development programs that selected patients using biomarkers, many of them genetic, had about twice the overall likelihood of approval of programs that did not.
Limits of genomics
- Genes are not destiny. For most common diseases, any single genetic variant has a small effect, and environment and lifestyle matter greatly.
- Most genetic studies have been done in people of European ancestry, which limits how well their findings apply to everyone.
- Finding a gene is not the same as having a drug. Many disease-linked proteins are hard to target with today's drug types.
Where genomics appears on Spectral Genomics
Profiles of experimental drugs on this site will note whether a drug's mechanism has human genetic support, because it is one of the strongest known predictors of clinical success. For how that fits into development odds, see Why Do Experimental Drugs Fail?
Sources
- National Human Genome Research Institute. A Brief Guide to Genomics.Regulator
- National Human Genome Research Institute. The Human Genome Project.Regulator
- MedlinePlus Genetics (National Library of Medicine). What is a gene?Regulator
- Nurk S, et al. The complete sequence of a human genome. Science. 2022;376(6588):44–53.Peer-reviewed
- Nelson MR, et al. The support of human genetic evidence for approved drug indications. Nature Genetics. 2015;47:856–860.Peer-reviewed
- Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024;629:624–629.Peer-reviewed
- Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine. 2006;354(12):1264–1272.Peer-reviewed
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.